WHO ICTRP trial
Bifidobacterium quadruple viable tablets (Siliankang) in the treatment of…
ChiCTR1800017721 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR1800017721 |
|---|---|
| Public title | Bifidobacterium quadruple viable tablets (Siliankang) in the treatment of diarrhea predominant irritable bowel syndrome study on the clinical efficacy and safety of signs: a randomized, double-blind, placebo-controlled, multicenter trial |
| Scientific title | Bifidobacterium quadruple viable tablets (Siliankang) in the treatment of diarrhea predominant irritable bowel syndrome study on the clinical efficacy and safety of signs: a randomized, double-blind, placebo-controlled, multicenter trial |
| Primary sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | Post-market |
| Countries | China |
| Conditions | Diarrhea predominant irritable bowel syndrom |
| Interventions | Experimental group:Bifidobacterium quadruple viable tablets ;Control group:placebo |
| Registration date | Aug 10, 2018 |
| Target size | Experimental group:150;Control group:150 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: